Re-evaluation of three ingredients to be planned within this year, KFDA says

Published: 2007-02-05 06:59:00

Updated: 2007-02-05 06:59:00

The Korea Food and Drug Administration (KFDA) said recently it will re-evaluate the bioequivalence testing results of simvastatin, felodipine and itraconazol within this year,
which was originally planned in 2008

The KFDA announcement came after Korean Medical Association (KMA) claimed that ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK